Sailong Pharmaceutical Group Co Ltd
002898
Company Profile
Business description
Sailong Pharmaceutical Group Co Ltd is a pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Contact
No. 47, Haibin South Road
2nd Floor, Everbright International Trade Center
Guangdong Province
Zhuhai519015
CHNT: +86 7563882971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
418
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
Aussie property manager lifts earnings expectations despite interest rate uncertainty.
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.20 | 66.70 | 0.75% |
| CAC 40 | 8,207.89 | 34.78 | 0.43% |
| DAX 40 | 25,177.80 | 7.09 | -0.03% |
| Dow JONES (US) | 50,644.47 | 182.79 | 0.36% |
| FTSE 100 | 10,505.01 | 13.62 | 0.13% |
| HKSE | 25,328.23 | 271.22 | -1.06% |
| NASDAQ | 26,674.73 | 18.55 | 0.07% |
| Nikkei 225 | 64,999.41 | 3.32 | 0.01% |
| NZX 50 Index | 13,227.81 | 158.07 | 1.21% |
| S&P 500 | 7,520.55 | 1.43 | 0.02% |
| S&P/ASX 200 | 8,717.70 | 65.50 | 0.76% |
| SSE Composite Index | 4,093.73 | 51.65 | -1.25% |